Chronic hepatitis C
Conditions
Interventions
Telaprevir reduction Peginterferon alpha 2b Ribavirin
Telaprevir Peginterferon alpha 2b Ribavirin reduction
Sponsors
Department of Hepatology, Osaka City University , Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The following chronic hepatitis C patients with Genotype 1 and high viral lord were eligible to enter the trial HCV-RNA >= 5.0 LogIU/mL WBC counts>=3,000/microL Neutrophil counts>=1,500/microL Hemoglobin concentration>=12g/dL Platelet counts>=90,000/microL Presence of liver biopsy is not asked Presence of the IFN treatment history is not asked Patients who provided written informed consent to participate the study prior to enrollment
Exclusion criteria
Exclusion criteria: The following patients were excluded women of childbearing potential and pregnancy, lactating women allergic to ribavirin or other nucleoside analogues an uncontrollable heart trouble( myocardial infarction, heart failure, or arrhythmia) hemoglobibopathy ( thalassemia, sickle cell disease) severe renal disease or Ccr<50mL/min severe depression or psychosomatic disorders severe liver disease autoimmune hepatitis or HBV drug allergy against interferon
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained Virological Response ( SVR ) at week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| ALT normalization Safety | — |
Countries
Japan
Contacts
Public ContactAkihiro Tamori
Osaka City University, Graduate School of Medicine Department of Hepatology
Outcome results
None listed